AAPL 193.32 +0.46 (+0.24%)MSFT 133.04 +0.1 (+0.08%)FB 181.4 +1.03 (+0.57%)ZNGA 6.2 +0.08 (+1.23%)NVDA 144.91 +0.48 (+0.33%)WBA 52.67 +0.01 (+0.02%)GOOG 1088.38 +1.34 (+0.12%)PIH 5.73 0 (0.00%)
AAPL 193.32 +0.46 (+0.24%)MSFT 133.04 +0.1 (+0.08%)FB 181.4 +1.03 (+0.57%)ZNGA 6.2 +0.08 (+1.23%)NVDA 144.91 +0.48 (+0.33%)WBA 52.67 +0.01 (+0.02%)GOOG 1088.38 +1.34 (+0.12%)PIH 5.73 0 (0.00%)

Cash Flow ABUS Quote Arbutus Bio

All | Income Statement | Balance Sheet | Cash Flow | Retained Earnings | PPE Schedule | Intangible and Goodwill Schedule
Year 20142015201620172018
NetIncome -39 -61 -384 -84 -57
Depreciation 1 1 1 0 0
DeferredIncomeT 0 -16 -105 -24 -4
StockBasedCompe 3 22 39 15 6
AccountsReceiva -2 1 1 0 -1
InventoryCS 0 0 0 0 0
AccountsPayable 6 -2 0 1 -1
OtherWorkingCap 13 -13 -1 3 -3
OtherNonCashIte -43 -82 -383 -85 -83
NetCashProvided -12 -55 -58 -49 -68
InvestmentsInPP -1 -2 -4 -7 -1
AcquisitionsNet 0 0 0 0 0
PurchasesOfInve 0 0 0 0 0
SalesMaturities 0 0 0 0 0
PurchasesOfInta 0 0 0 0 0
OtherInvestingA -42 10 -95 35 -3
NetCashUsedForI -43 8 -99 28 -4
DebtIssued 0 0 12 0 0
DebtRepayment 0 0 0 0 -12
CommonStockIssu 56 142 0 0 0
CommonStockRepu 0 0 0 0 0
DividendPaid 0 0 0 0 0
OtherFinancingA 4 2 1 0 1
NetCashProvided 61 144 13 49 56
NetChangeInCash 3 95 -143 31 -17
CashAtBeginning 69 72 167 23 54
CashAtEndOfPeri 72 167 23 54 37
Arbutus Biopharma Corporation income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Arbutus Biopharma Corporation FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.